ABT-263 Enhances Sensitivity to Metformin and 2-Deoxyglucose in Pediatric Glioma by Promoting Apoptotic Cell Death

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Levesley, Jane ^a   Steele, Lynette ^a   Taylor, Claire ^a   Sinha, Priyank ^a   Lawler, Sean E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; CASPASE 3; CASPASE 7; CASPASE INHIBITOR; DEOXYGLUCOSE; METFORMIN; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; ANILINE DERIVATIVE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE; PEPTIDE CHLOROMETHYL KETONE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; GLIOMA; HUMAN; HUMAN CELL; INHIBITION KINETICS; METABOLIC STRESS; PROTEIN FAMILY; CHILD; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; NONPARAMETRIC TEST; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; AMINO ACID CHLOROMETHYL KETONES; ANILINE COMPOUNDS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; DEOXYGLUCOSE; DRUG SYNERGISM; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; METFORMIN; STATISTICS, NONPARAMETRIC; SULFONAMIDES;

EID: 84877850185     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064051     Document Type: Article

References (38)

1. Hargrave D, (2009) Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg 23: 351-363.
2. Jones C, Perryman L, Hargrave D, (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 9: 400-413.
3. MacDonald TJ, Aguilera D, Kramm CM, (2011) Treatment of high-grade glioma in children and adolescents. Neuro Oncol 13: 1049-1058.
4. Sanders RP, Kocak M, Burger PC, Merchant TE, Gajjar A, et al. (2007) High-grade astrocytoma in very young children. Pediatr Blood Cancer 49: 888-893.
5. Warburg O, Wind F, Negelein E, (1927) THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol 8: 519-530.
6. Dang CV, Hamaker M, Sun P, Le A, Gao P, (2011) Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 89: 205-212.
7. Vander Heiden MG, (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
8. Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, et al. (2012) Metabolism of [U-(13) C]glucose in human brain tumors in vivo. NMR Biomed 25: 1234-1244.
9. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, et al. (2012) Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15: 827-837.
10. Mischel PS, (2012) HOT models in flux: mitochondrial glucose oxidation fuels glioblastoma growth. Cell Metab 15: 789-790.
11. Katayama M, Kawaguchi T, Berger MS, Pieper RO, (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14: 548-558.
12. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, et al. (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71: 4366-4372.
13. Blandino G, Valerio M, Cioce M, Mori F, Casadei L, et al. (2012) Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun 3: 865.
14. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752.
15. Rattan R, Giri S, Hartmann LC, Shridhar V, (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178.
16. Song CW, Lee H, Dings RP, Williams B, Powers J, et al. (2012) Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2: 362.
17. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, et al. (2011) Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2: e199.
18. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, et al. (2007) Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64: 1290-1302.
19. Soritau O, Tomuleasa C, Aldea M, Petrushev B, Susman S, et al. (2011) Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON 16: 282-289.
20. Ralser M, Wamelink MM, Struys EA, Joppich C, Krobitsch S, et al. (2008) A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc Natl Acad Sci U S A 105: 17807-17811.
21. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475.
22. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, et al. (2011) Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 10: 2350-2362.
23. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, et al. (2009) Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res 69: 4225-4234.
24. Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, et al. (2009) Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One 4: e5209.
25. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482: 226-231.
26. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, et al. (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44: 251-253.
27. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, et al. (2008) Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656.
28. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C, (2011) Sugar-free approaches to cancer cell killing. Oncogene 30: 253-264.
29. Munoz-Pinedo C, El Mjiyad N, Ricci JE, (2012) Cancer metabolism: current perspectives and future directions. Cell Death Dis 3: e248.
30. Robinson GL, Dinsdale D, Macfarlane M, Cain K (2012) Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene.
31. Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, et al. (2011) Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One 6: e24102.
32. Zagorodna O, Martin SM, Rutkowski DT, Kuwana T, Spitz DR, et al. (2012) 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines. Oncogene 31: 2738-2749.
33. Trent J, Meltzer P, Rosenblum M, Harsh G, Kinzler K, et al. (1986) Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc Natl Acad Sci U S A 83: 470-473.
34. Alavian KN, Li H, Collis L, Bonanni L, Zeng L, et al. (2011) Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nat Cell Biol 13: 1224-1233.
35. Shim H, Chun YS, Lewis BC, Dang CV, (1998) A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A 95: 1511-1516.
36. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, et al. (1996) Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35: 103-111.
37. Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, et al. (2009) Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther 5Suppl 1: S21-26.
38. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, et al. (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208: 313-326.